Hypertension management and drug-related problems. A case report of the 23-year history of Mr. Jonas.
Drug related problems
Hypertension
Hypertension management
Pharmacistintervention
Journal
Exploratory research in clinical and social pharmacy
ISSN: 2667-2766
Titre abrégé: Explor Res Clin Soc Pharm
Pays: United States
ID NLM: 9918266300706676
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
20
07
2023
accepted:
21
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Arterial hypertension is a lifelong disease, which management is recognized as the most effective way to reduce cardiovascular mortality. Even though there is extensive evidence on the benefits of lifestyle modification and antihypertensive treatment, many patients with hypertension do not reach blood pressure targets. This paper aims to review the history of antihypertensive treatment of one patient and identify the drug related problems that occurred over the study period. In this case report, the patient's health record was studied, guidelines checked and a semi-structured interview conducted. Drug related problems were identified and possible pharmacist interventions were introduced. Drug related problems that could have contributed to the lack of hypertension control were adherence, side effects and disease-drug interaction. Identified pharmacists' interventions ranged from managing self-medication, to collaboration with general practitioner to change prescribing, and counselling the patient on medication use, including adherence. Even though the drug related problems were not that serious in the studied case, the patient could have valued from pharmacist intervention.
Identifiants
pubmed: 37601158
doi: 10.1016/j.rcsop.2023.100313
pii: S2667-2766(23)00094-X
pmc: PMC10433230
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100313Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
One author declares the following personal relationships which may be considered as potential competing interests: Indre Treciokiene is a daughter of the patient studied.
Références
Can Respir J. 2018 Aug 19;2018:6060581
pubmed: 30210645
Gerontologist. 2009 Aug;49(4):447-62
pubmed: 19460887
PLoS One. 2014 Jan 15;9(1):e84238
pubmed: 24454721
Prev Med. 2017 Jun;99:269-276
pubmed: 28315760
Eur J Cardiovasc Nurs. 2021 Apr 13;20(2):91-92
pubmed: 33620471
J Hypertens. 2007 Jun;25(6):1105-87
pubmed: 17563527
Res Social Adm Pharm. 2022 Apr;18(4):2559-2568
pubmed: 33965357
Pharmaceutics. 2021 Jul 20;13(7):
pubmed: 34371791
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Multidiscip Healthc. 2020 Jul 20;13:635-645
pubmed: 32764955
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Circ Res. 2019 Mar 29;124(7):1124-1140
pubmed: 30920917
BMC Fam Pract. 2021 Apr 5;22(1):63
pubmed: 33820547
J Clin Hypertens (Greenwich). 2008 Aug;10(8):644-6
pubmed: 18772648
J Am Heart Assoc. 2019 Nov 19;8(22):e013627
pubmed: 31711390
PLoS One. 2018 Oct 23;13(10):e0206120
pubmed: 30352096
Drugs Aging. 2016 Mar;33(3):199-204
pubmed: 26961696
Patient Educ Couns. 2018 Jul;101(7):1175-1192
pubmed: 29628282
Health Policy. 2008 Dec;88(2-3):258-68
pubmed: 18468713
Nat Rev Nephrol. 2020 Apr;16(4):223-237
pubmed: 32024986
Lancet. 2019 Aug 24;394(10199):639-651
pubmed: 31327564
Open Heart. 2018 Jan 3;5(1):e000687
pubmed: 29344376
Front Pharmacol. 2021 Aug 17;12:698907
pubmed: 34489695
Hypertension. 2019 Sep;74(3):450-457
pubmed: 31352827
J Pharm Pract. 2021 Jun;34(3):480-492
pubmed: 32067555
J Hypertens. 2003 Jun;21(6):1011-53
pubmed: 12777938
Br J Clin Pharmacol. 2014 Dec;78(6):1238-47
pubmed: 24966032
J Hypertens. 2004 Jan;22(1):11-9
pubmed: 15106785
J Hypertens. 2013 Oct;31(10):1925-38
pubmed: 24107724
Res Social Adm Pharm. 2020 Sep;16(9):1155-1165
pubmed: 31959565
BMC Pharmacol Toxicol. 2017 Jun 27;18(1):52
pubmed: 28655357